publication date: Oct. 1, 2014

html NCI CTEP.html

NCI CTEP-Approved Trials for the Month of September

The National Cancer Institute Cancer Therapy Evaluation Program approved the following clinical research studies last month. For further information, contact the principal investigator listed.

Phase I

9605: Phase I Study of Ganetespib and Ziv-Aflibercept in Patients with Advanced Gastrointestinal Carcinomas, Non-Squamous Non-Small Cell Lung Carcinomas, Urothelial Carcinomas, and Sarcomas. National Cancer Institute Developmental Therapeutics Clinic; Kummar, Shivaani. (301) 435-0517

AMC-091: Phase I and Pharmacokinetic Study of Ibrutinib in HIV-Infected Patients with Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma or Multiple Myeloma. AIDS-Associated Malignancies Clinical Trials Consortium; Kasamon, Yvette L. (410) 955-8839

Phase II

AOST1322: A Phase II Study of Eribulin (IND# 122686, NSC# 707389) in Recurrent or Refractory Osteosarcoma. Children’s Oncology Group; Isakoff, Michael Scott. (860) 545-9630

Phase III

A081105: Randomized Double Blind Placebo Controlled Study of Erlotinib or Placebo in Patients with Completely Resected Epidermal Growth Factor Receptor (EGFR) Mutant Non-Small Cell Lung Cancer (NSCLC). Alliance for Clinical Trials in Oncology; Govindan, Ramaswamy. (314) 362-5737

A221304: A Phase III Placebo-Controlled, Randomized Three-Arm Study of Doxepin and a Topical Rinse in the Treatment of Acute Oral Mucositis Pain in Patients Receiving Radiotherapy With or Without Chemotherapy. Alliance for Clinical Trials in Oncology; Miller, Robert C. (507) 284-2669

NRG-GI001: Randomized Phase III Study of Focal Radiation Therapy for Unresectable, Localized Intrahepatic Cholangiocarcinoma. NRG Oncology; Hong, Theodore Sunki. (617) 726-5866

Pilot Phase

9671: … Continue reading CCL Sept – NCI CTEP

To access this members-only content, please log in.
Institutional subscribers, please log in with your IP.
If you're not a subscriber why not join today?
To gain access to the members only content click here to subscribe.
You will be given immediate access to premium content on the site.
Click here to join.

Copyright (c) 2020 The Cancer Letter Inc.